The role of PPAR-gamma C161T polymorphism in colorectal cancer susceptibility

Basit Öğe Kaydı
dc.authoridBahar Canbay Torun / 0000-0002-6353-6692en_US
dc.authorscopusidBahar Canbay Torun / 57191379685
dc.authorwosidBahar Canbay Torun / ADU-6077-2022en_US
dc.contributor.authorKurnaz-Gomleksiz , Ozlem
dc.contributor.authorCanbay Torun, Bahar
dc.contributor.authorIsbir,Turgay
dc.contributor.authorBulut,Turker
dc.contributor.authorSokucu, Necmettin
dc.contributor.authorYilmaz-Aydogan, Hulya
dc.contributor.authorCanbay, Emel
dc.date.accessioned2022-06-28T07:40:50Z
dc.date.available2022-06-28T07:40:50Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground/aim: This study aimed to determine the role of the peroxisome proliferator-activated receptor-gamma (PPARg) C161T genotype and allele frequencies in predisposition to colorectal cancer (CRC). Patients and methods: PPARg C161T (His447His; rs3856806) gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in patients with CRC (n=101) and controls (n=238). Results: The T161 allele (CT+TT genotypes) of PPARg C161T polymorphism was associated with CRC development (p<0.001; OR=3.239, 95%CI=1.997-5.252). Subgroup analysis showed that the T161 allele was associated with a 3.056-fold increased risk for colon cancer (CC) (p<0.001; 95%CI=1.709-5.464) and 3.529-fold increased risk for rectal cancer (RC) (p<0.001; 95%C=1.784-6.981). Frequencies of the T161 allele were also higher in total CRC and CC patients with poorly differentiated tumors (p<0.001, c2=30,601, OR=3.109; 95%CI=1.970-4.906 and p<0.001, Fisher exact test, respectively). Conclusion: PPARg T161 allele carriers have increased risk for developing CRC.en_US
dc.identifier.citationKurnaz-Gomleksiz O, Torun BC, Isbir T, Bulut T, Sokucu N, Yilmaz-Aydogan H, Canbay E. The Role of PPAR-gamma C161T Polymorphism in Colorectal Cancer Susceptibility. In Vivo. 2022 Jul-Aug;36(4):1911-1915. doi: 10.21873/invivo.12911. PMID: 35738614.en_US
dc.identifier.doi10.21873/invivo.12911en_US
dc.identifier.endpage1915en_US
dc.identifier.issn0258-851Xen_US
dc.identifier.issue14en_US
dc.identifier.pmid35738614en_US
dc.identifier.scopus2-s2.0-85132680880en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1911en_US
dc.identifier.urihttp://doi.org/10.21873/invivo.12911
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2949
dc.identifier.volume36en_US
dc.identifier.wosWOS:000818929900029en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorCanbay Torun, Bahar
dc.language.isoenen_US
dc.publisherVivoen_US
dc.relation.ispartofIn Vivoen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPPARg C161T Polymorphismen_US
dc.subjectTurkish Populationen_US
dc.subjectColorectal cancer (CRC)en_US
dc.titleThe role of PPAR-gamma C161T polymorphism in colorectal cancer susceptibilityen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
1911.full.pdf
Boyut:
103.24 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu